<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01493440</url>
  </required_header>
  <id_info>
    <org_study_id>IVFAS1103</org_study_id>
    <nct_id>NCT01493440</nct_id>
  </id_info>
  <brief_title>Atosiban Improves Implantation and Pregnancy Rates in Patients With Repeated Implantation Failure</brief_title>
  <official_title>Atosiban Improves Implantation and Pregnancy Rates in Patients With Repeated Implantation Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>An Sinh Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Vietnam National University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>An Sinh Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Atosiban, administered at embryo transfer, can improve the implantation rate and the clinical
      pregnancy rate in patients with repeated implantation failure undergoing IVF-ET (in-vitro
      fertilization and embryo transfer).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Atosiban is a mixed oxytocin and vasopressin V1A receptor antagonist.Combined antagonism at
      oxytocin and vasopressin V1A receptors reduces uterine contractions with a corresponding
      decrease in intrauterine production of prostaglandin F2alpha and improved uterine blood
      supply. These effects are of potential benefit for implantation support during IVF-ET cycles.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical pregnancy</measure>
    <time_frame>5 weeks after intervention</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">71</enrollment>
  <condition>Repeated Implantation Failure</condition>
  <arm_group>
    <arm_group_label>Atosiban</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>atosiban</intervention_name>
    <description>Atosiban was administered as a 6.75mg IV bolus dose 30 minutes prior to embryo transfer followed by a 1-hour IV infusion at dose of 18 mg/h then a 2-hour IV infusion at 6 mg/h.</description>
    <arm_group_label>Atosiban</arm_group_label>
    <other_name>Tractocile</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  had repeated implantation failure

          -  have at least 1 good quality embryo for transfer

        Exclusion Criteria:

          -  uterine abnormalities that could compromise the implantation process (e.g. fibroids,
             endometrial polyp, bicornuate uterus, adhesion of uterine cavity)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lan TN Vuong, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Medicine and Pharmacy of Ho Chi Minh City</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>IVFAS, An Sinh Hospital</name>
      <address>
        <city>Ho Chi Minh City</city>
        <state>Ho Chi Minh</state>
        <zip>8</zip>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Vietnam</country>
  </location_countries>
  <reference>
    <citation>Moraloglu O, Tonguc E, Var T, Zeyrek T, Batioglu S. Treatment with oxytocin antagonists before embryo transfer may increase implantation rates after IVF. Reprod Biomed Online. 2010 Sep;21(3):338-43. doi: 10.1016/j.rbmo.2010.04.009. Epub 2010 Apr 18.</citation>
    <PMID>20638340</PMID>
  </reference>
  <verification_date>December 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 14, 2011</study_first_submitted>
  <study_first_submitted_qc>December 15, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2011</study_first_posted>
  <last_update_submitted>December 16, 2011</last_update_submitted>
  <last_update_submitted_qc>December 16, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 20, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ho Chi Minh City University of Medicine and Pharmacy</investigator_affiliation>
    <investigator_full_name>Vuong Thi Ngoc Lan</investigator_full_name>
    <investigator_title>Lecturer and Researcher, Department of Obstetrics and Gynecology</investigator_title>
  </responsible_party>
  <keyword>atosiban</keyword>
  <keyword>clinical pregnancy</keyword>
  <keyword>implantation rate</keyword>
  <keyword>uterine contractility</keyword>
  <keyword>IVF-ET</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atosiban</mesh_term>
    <mesh_term>Vasotocin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

